@WHO: The panel of experts developing the guidelines also looked at two other drugs for severe & critical #COVID19: ruxolitinib and tofacitinib. Given their uncertain effects, WHO made a conditional recommendation against their use https://t.co/UAc21Wgxbl https://t.co/Z39mSKrOv5

http://twitter.com/WHO
via IFTTT